Immunogenicity and safety evaluation of FluGuard® (seasonal quadrivalent recombinant influenza vaccine manufactured by Nivad Pharmed Salamat), in comparison with Vaxigrip Tetra (quadrivalent inactivated influenza vaccine manufactured by Sanofi Pasteur)

Inclusion criteria:

Age between 9-18 Have general health Sign informed consent for volunteers (over 14) Parents sign the informed consent form Be able to accompany with the visit programs and study process

Exclusion criteria:

History of previous vaccinations against influenza strains used in injectable vaccines during the new influenza season History of allergy to egg or Vaxigrip or Its components Any type of disease with evidence of acute viral respiratory infection Any conditions that prevent the study volunteer from enroll, such as: Thrombocytopenia (platelets less than 150,000), Coagulopathy, Receiving anticoagulants during last 3 months, Prohibition of IM drug administration, History of congenial or immunodeficiency or autoimmune disease, Acute phase of infectious disease, such as having a temperature of more than 37.7 °C during the 7 days before enrollment Receiving live attenuated vaccine within 30 days before enrollment Receiving immunomodulatory or immunosuppressant drugs, Receiving long-term systemic corticosteroid (corticosteroids for more than two weeks in the last 3 months or receiving prednisolone more than 2 mg/kg daily or its equivalent dose for more than 10 days) Receiving immunoglobulins and blood products within 3 months before enrollment History of Guillain-Barre syndrome Conditions such as neurological disorders and seizure under treatment (seizure history is not considered as exclusion criteria.) history of transplant, Cardiovascular disease, Asthma History of malignancies and radiotherapy during last 6 months Married women under the age of 18, pregnant or pregnancy planning in female volunteers

Target sample size: 734